South Africa reports H5N1 bird flu on poultry farms, international agency says
The outbreaks have killed 1,150 poultry birds, Paris-based WOAH said in a notification, citing South African authorities.
(Reporting by Gus TrompizEditing by Ros Russell)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Free Malaysia Today
9 hours ago
- Free Malaysia Today
Pharma shares slump after Trump price threat
Donald Trump is targeting cutting US drug prices, which are among the world's highest. (AFP pic) PARIS : Shares in European pharmaceutical firms slumped on Friday following a threat by president Donald Trump to punish them if they don't lower prices for medicines in the US. Shares in Novo Nordisk, the Danish maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, saw shares drop 4.5% shortly after trading got under way in Copenhagen. Shares in Britain's AstraZeneca fell 2.8% in London, while Sanofi fell 1.1% in Paris. Meanwhile shares in Novartis shed 0.9% and Roche 1.0% after Trump announced Swiss goods will face a 39% tariff starting next week. Trump told major pharmaceutical firms Thursday to lower prices or face punishment, as he moved to give Americans relief from medicine costs much higher than elsewhere in the world. In letters to 17 drug companies published on his platform Truth Social, Trump said he wants the firms to work with his administration to institute a series of changes within 60 days. 'If you refuse to step up we will deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices,' Trump wrote without specifying what the consequences would entail. Trump is following up on an executive order he signed in May to address US drug prices that are among the highest in the world – more than three times what people in similarly developed countries pay, the White House said Thursday.
Malaysian Reserve
20 hours ago
- Malaysian Reserve
BioLab Holdings, Inc. Launches Its Largest Clinical Trial to Date Evaluating Human Placental Membrane Products
Study Will Compare Four Amnion-Based Therapies Plus Standard of Care to Standard of Care Alone in Chronic Wound Management PHOENIX, July 31, 2025 /PRNewswire/ — BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in regenerative wound care, has initiated its most comprehensive clinical trial to date. The multicenter, prospective, randomized controlled study will evaluate the efficacy of four human placental membrane (HPM) products in combination with standard of care (SOC) compared to SOC alone in the treatment of nonhealing diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trial, formally titled 'A Multicenter, Prospective, Randomized Controlled Modified Multi-Platform Trial Assessing the Efficacy of Human Placental Membrane Products and Standard of Care Versus Standard of Care Alone in the Management of Nonhealing Diabetic Foot Ulcers and Venous Leg Ulcers (BIOCAMP),' will enroll 650 subjects across up to 30 clinical sites nationwide. 'This study represents a major milestone in our commitment to advancing wound care through rigorous clinical research,' said Dr. Marshall Medley, chief medical officer at BioLab. 'By evaluating our full suite of amnion-based products in a real-world setting, we aim to provide clinicians with robust data to guide treatment decisions for patients with chronic wounds.' Participants will be randomized to receive one of four BioLab products—Tri-Membrane Wrap™ (HPM-1), Membrane Wrap™ (HPM-2), Membrane Wrap-Lite™ (HPM-3), or Membrane Wrap-Hydro™ (HPM-4)—in addition to SOC, or SOC alone. Treatments will be applied weekly for up to 12 weeks or until complete wound closure is achieved and confirmed two weeks later. Optional weekly visits will allow for dressing changes in both study arms. The study is designed to capture real-world clinical outcomes and support the growing body of evidence for the use of placental-derived allografts in chronic wound management. For more information on BioLab Holdings, Inc. and its regenerative wound care solutions, visit About BioLab Holdings, Holdings, Inc. is a Phoenix-based medical manufacturer focused on wound healing and regenerative medicine. Its product portfolio includes Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™ and Membrane Wrap – Hydro™, all derived from human amniotic membrane. These minimally manipulated allografts are designed to preserve the tissue's natural properties and support healing. BioLab is committed to delivering safe, high-quality products through innovation, education and exceptional customer service. Learn more at Contact: Kwyn LowePhone: 406.314.5120Email: kwyn@
Free Malaysia Today
a day ago
- Free Malaysia Today
Health ministry drops case against doctor for dispensing ivermectin
Health ministry officials had seized the antiparasitic drug found in Dr Che Amir Farid Che Isahak's clinic, arguing that it was not a registered product. (Reuters pic) PETALING JAYA : The health ministry has withdrawn a criminal case against a doctor for possessing and dispensing ivermectin. Dr Che Amir Farid Che Isahak said the ministry's decision to drop the case yesterday followed a ruling made by the Federal Court four months ago on a related matter. In March, the apex court unanimously decided to uphold doctors' right to give patients ivermectin. Health ministry officials had raided Che Amir's clinic in Ampang in 2021 during the peak of the Covid-19 pandemic. The raid followed reports that two patients, unconnected to Che Amir, had self-prescribed ivermectin and allegedly suffered acute poisoning and breathing difficulties. Officials seized the antiparasitic drug found in the clinic, arguing that it was not a registered product. They also claimed that the doctor was not legally permitted to sell or dispense the drug. Che Amir was subsequently charged in the magistrates' court with selling and dispensing the drug. When contacted, Che Amir said although the case resulted from the use of ivermectin for Covid-19 patients, the court's decision allows doctors who are proponents of the drug to use it for the prevention or treatment of any other types of diseases or conditions. 'And we can now safely prescribe and dispense ivermectin without fear of being raided anymore.' He also said more diseases had been found to be amenable to treatment with ivermectin, including cancer. However, he said while there had been many preclinical studies, no clinical study had been conducted. 'Ivermectin is emerging as a treatment for many types of cancer. 'For now there are only case reports and testimonies on the treatment of cancer with ivermectin. I hope that clinical trials will be conducted soon.'
